Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial.
Yiqiao XinA DaviesL McCombieA BriggsC-M MessowE GrieveW S LeslieR TaylorM E J LeanPublished in: Diabetic medicine : a journal of the British Diabetic Association (2020)
Remission of Type 2 diabetes within 1-year can be achieved at a cost below the annual cost of diabetes (including complications). Providing a reasonable proportion of remissions can be maintained over time, with multiple medical gains expected, as well as immediate social benefits, there is a case for shifting resources within diabetes care budgets to offer support for people with Type 2 diabetes to attempt remission. (Clinical Trial Registry No.: ISRCTN03267836).
Keyphrases
- type diabetes
- primary care
- randomized controlled trial
- study protocol
- clinical trial
- disease activity
- ulcerative colitis
- glycemic control
- healthcare
- cardiovascular disease
- body mass index
- weight loss
- physical activity
- rheumatoid arthritis
- mental health
- risk factors
- phase ii
- weight gain
- metabolic syndrome
- skeletal muscle
- phase iii